Keeping Up With “The Energizer Bunny”: US FDA Commissioner Gottlieb As A Boss
Executive Summary
Three center directors agree that Gottlieb’s facility for public communications is a boon for FDA – and that the commissioner is appropriately hands-off when it comes to day-to-day decisions on scientific or policy issues.
You may also be interested in...
“Nobody Was Armed At NCI”: US FDA Head Sharpless Adjusts To Life As Regulator
Acting commissioner is entering the usual learning curve for new leaders of the agency. It’s a reminder of how unusual it was to skip that step under his predecessor.
Gottlieb's Greatest Strength As US FDA Commissioner? Stability
Amid all the praise for his raising of FDA's profile and aggressive policy stances, Scott Gottlieb's most valuable contribution while in office may have been leaving the agency fundamentally unchanged, an important lesson for incoming Acting Commissioner Norman Sharpless.
US FDA May Largely Avoid House Democrats' Investigation Agenda
Drug pricing hearings likely will involve FDA, but most pressing issue facing agency following midterms may be whether Commissioner Gottlieb will depart.